Why did J&J hit pause on its COVID-19 vaccine trial? Stay tuned, execs say

Pausing a trial due to unexpected illnesses is not uncommon, especially in large studies like this one, said Johnson & Johnson Chief Financial Officer Joseph Wolk. (Raysonho/CC0)

Johnson & Johnson has put its late-stage COVID-19 vaccine study on hold because a patient has fallen ill. The pause comes just weeks after the company kicked off the 60,000-patient study and about a month after AstraZeneca suspended its own COVID-19 study for similar reasons.

J&J paused the study due to an “unexplained illness in a study participant,” Stat reported Monday evening.

“Right now, we’re waiting for the independent drug safety monitoring board (DSMB) to do their analysis … We still don’t know whether it’s in the placebo arm or the vaccination arm,” J&J Chief Financial Officer Joseph Wolk said on CNBC Tuesday morning.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

RELATED: AstraZeneca's COVID-19 vaccine hold sparks reassessment of race

Pausing a trial because of unexpected illnesses is not uncommon, especially in large studies like this one, Wolk said, a sentiment echoed by Mathai Mammen, M.D., Ph.D., the R&D chief at J&J’s Janssen unit, on the company’s third-quarter earnings call.

“We were informed of unexpected illness Sunday evening. DSMB was informed immediately,” Mammen said, adding that there's “a very defined and well thought through process at J&J that follows high standards,” and the company “followed all of that to the letter here.”

“It’ll be a few days at minimum for the right set of information to be gathered and evaluated,” Mammen said.

RELATED: J&J starts COVID-19 vaccine phase 3, eyes early 2021 approval

AstraZeneca paused its own study early last month because a patient developed transverse myelitis, or inflammation of the spinal cord that can be triggered by infections. It restarted the trial in the U.K. a week later, with sites in other countries getting back on track soon after. It’s still on hold in the U.S.

Both J&J and AstraZeneca are part of Operation Warp Speed, the U.S. government's effort to deliver 100 million doses of a viable COVID-19 vaccine by January 2021. And that's not all they have in common—both are developing adenovirus-based vaccines, unlike Warp Speed peers Pfizer and Moderna, which are working on mRNA-based jabs.

Suggested Articles

GE Healthcare has launched a new algorithm that can read X-rays and help assess the correct placement of ventilator tubes in critical patients.

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.